Strongbridge Biopharma plc to Present at the Canaccord Genuity 37th Annual Growth Conference
August 10 2017 - 7:30AM
Strongbridge Biopharma plc (NASDAQ:SBBP), a global
commercial-stage biopharmaceutical company focused on the
development and commercialization of therapies for rare diseases
with significant unmet needs, today announced that management
will present at the Canaccord Genuity 37th Annual Growth
Conference, taking place August 9-10, 2017 at
the InterContinental in Boston.
Matthew Pauls, president and chief executive
officer of Strongbridge Biopharma, will provide a corporate
overview on Thursday, August 10 at 3:00 p.m. ET. The
presentation will be webcast live and archived on the “Events &
Presentations” page in the Investor section of the Company’s
website at www.strongbridgebio.com.
About Strongbridge BiopharmaStrongbridge
Biopharma is a commercial-stage global biopharmaceutical
company focused on the development and commercialization of
therapies for rare diseases with significant unmet needs.
Strongbridge's first commercial product is KEVEYIS®
(dichlorphenamide), the first and only FDA-approved treatment for
hyperkalemic, hypokalemic, and related variants of Primary Periodic
Paralysis. KEVEYIS has orphan drug exclusivity status in the U.S.
through August 7, 2022. In addition to establishing this
neuromuscular disease franchise, the Company has a clinical-stage
pipeline of therapies for rare endocrine diseases. Strongbridge's
lead compounds include RECORLEV™ (levoketoconazole), a cortisol
synthesis inhibitor currently being studied for the treatment of
endogenous Cushing's syndrome, and veldoreotide, a next-generation
somatostatin analog being investigated for the treatment of
acromegaly, with potential additional applications in Cushing's
syndrome and neuroendocrine tumors. Both RECORLEV and veldoreotide
have received orphan designation from the U.S. Food and Drug
Administration and the European Medicines Agency. For more
information, visit www.strongbridgebio.com.
Contacts:
Corporate and Media Relations
Elixir Health Public Relations
Lindsay Rocco
+1 862-596-1304
lrocco@elixirhealthpr.com
Investor Relations
U.S.:
The Trout Group
Marcy Nanus
+1 646-378-2927
mnanus@troutgroup.com
Europe:
First House
Mitra Hagen Negård
+47 21 04 62 19
strongbridgebio@firsthouse.no
USA
900 Northbrook Drive
Suite 200
Trevose, PA 19053
Tel. +1 610-254-9200
Fax. +1 215-355-7389
Strongbridge Biopharma (NASDAQ:SBBP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Strongbridge Biopharma (NASDAQ:SBBP)
Historical Stock Chart
From Apr 2023 to Apr 2024